Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATI-2138 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ATI-2138 | EXPERIMENTAL | ATI-2138 oral tablets BID |
| Name | Type | Description |
|---|---|---|
| ATI-2138 | DRUG | ATI-2138 Oral Tablets BID |
Inclusion Criteria: * Able to comprehend and willing to sign the IRB approved ICF/assent prior to administration of study-related procedures. * Male patients or non-pregnant, non-nursing female patients 18 to 60 years old, inclusive, at the time of informed consent/assent. * Have at least a 1-year ...
Top 20 of 26 competitors
ATI-2138 is an investigational small molecule being developed for the treatment of moderate to severe atopic dermatitis in adults. It is not yet approved for any indication and remains in clinical development, with a Phase 2 study completed in adult participants with atopic dermatitis.
ATI-2138 targets ITK, which stands for interleukin-2 inducible T cell kinase. ITK is a kinase enzyme involved in T cell signaling. By targeting ITK, ATI-2138 is designed to modulate T cell driven inflammatory pathways relevant to atopic dermatitis.
ATI-2138 is being developed by Aclaris Therapeutics, Inc., which trades on the Nasdaq under the ticker ACRS. Aclaris is a biopharmaceutical company focused on developing therapies in immunology and dermatology, and ATI-2138 is one of its clinical-stage assets.
ATI-2138 is in Phase 2 development. A Phase 2 study in adult participants with moderate to severe atopic dermatitis has been completed. The drug is investigational and has not been approved by the FDA for any indication.
ATI-2138 has been studied in one clinical trial, NCT06585202, titled Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis. This Phase 2 trial enrolled 14 participants in the United States and is now completed. It was an uncontrolled study without randomization or blinding.